je.st
news
Home
› Translarna Granted Orphan Drug Designation In The U.S. And Europe For The Treatment Of Mucopolysaccharidosis I
Translarna Granted Orphan Drug Designation In The U.S. And Europe For The Treatment Of Mucopolysaccharidosis I
2014-12-29 01:43:03| drugdiscoveryonline Home Page
PTC Therapeutics, Inc. (Nasdaq: PTCT) today announced that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted orphan-drug designation (ODD) to Translarna™ (ataluren) for the treatment of patients with Mucopolysaccharidosis I (MPS I)
Tags: of
i
europe
treatment
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||